How can resistant hypertension be identified and prevented?

Nature Reviews Cardiology

Volumn 10, Issue 5, 2013, Pages 293-296

  Solini, Anna ^a   Ruilope, Luis M ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; NIFEDIPINE; SPIRONOLACTONE;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DIETARY INTAKE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESISTANT HYPERTENSION; REVIEW; SALT INTAKE; SEXUAL DYSFUNCTION; SLEEP DISORDERED BREATHING; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DIAGNOSTIC ERRORS; DIET, SODIUM-RESTRICTED; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; SODIUM CHLORIDE, DIETARY; TREATMENT OUTCOME;

EID: 84876928010     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.23     Document Type: Review

References (42)

1. Ruilope, L. M. Current challenges in the clinical management of hypertension. Nat. Rev. Cardiol. 9, 267-275 (2012).
2. Calhoun, D. A. et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403-1419 (2008).
3. Egan, B. M., Zhao, Y., Axon, R. N., Brzezinski, W. A. & Ferdinand, K. C. Uncontrolled and apparent treatment resistant hypertension in the United States, 1998 to 2008. Circulation 124, 1046-1048 (2011).
4. Pimenta, E. & Calhoun, D. A. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 125, 1594-1596 (2012).
5. de la Sierra, A. et al. Clinical features of 8,295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57, 898-902 (2011).
6. de la Sierra, A. et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J. Hypertens. 30, 1211-1216 (2012).
7. Phillips, L. S. & Twombly J. G. It's time to overcome clinical inertia. Ann. Intern. Med. 148, 783-785 (2008).
8. Turchin, A., Shubina, M., Chodos, A. H., Einbinder, J. S. & Pendergrass, M. L. Effect of board certification on antihypertensive treatment intensification in patients with diabetes mellitus. Circulation 117, 623-628 (2008).
9. Heisler, M. et al. When more is not better: Treatment intensification among hypertensive patients with poor medication adherence. Circulation 117, 2884-2892 (2008).
10. Mancia, G. et al. 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105-1187 (2007).
11. Chobanian, A. V. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
12. Viswanathan, M. et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: A systematic review. Ann. Intern. Med. 157, 785-795 (2012).
13. Schroeder, K., Fahey, T. & Ebrahim, S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch. Intern. Med. 164, 722-732 (2004).
14. Basile, J. The importance of prompt blood pressure control. J. Clin. Hypertens. (Greenwich) 10 (Suppl. 1), 13-19 (2008).
15. Berlowitz, D. R. & Franklin, S. The clock is ticking: The case for achieving more rapid control of hypertension. J. Clin. Hypertens. (Greenwich) 12, 323-327 (2010).
16. Daugherty, S. L. et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125, 1635-1642 (2012).
17. Bobrie, G. et al. Sequential nephron blockade versus sequential renin- angiotensin system blockade in resistant hypertension: A prospective, randomized, open blinded endpoint study. J. Hypertens. 30, 1656-1664 (2012).
18. Acelajado, M. C. & Calhoun, D. A. Aldosteronism and resistant hypertension. Int. J. Hypertens. http://dx.doi.org/10.4061/2011/837817.
19. Gaddam, K. et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study. Hypertension. 55, 1137-1142 (2010).
20. Václavík, J. et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): A randomized, double-blind, placebo-controlled trial. Hypertension 57, 1069-1075 (2011).
21. Calhoun, D. A. & White, W. B. Effectiveness of the selective aldosterone antagonist eplerenone in treating resistant hypertension. J. Am. Soc. Hypertens. 2, 462-468 (2008).
22. Gashti, C. N. & Bakris, G. L. The role of calcium antagonists in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 13, 155-161 (2004).
23. Whelton, P. K. et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation 126, 2880-2889 (2012).
24. He, F. J. & MacGregor, G. A. Effect of modest salt reduction on blood pressure: A meta-analysis of randomized trials. Implications for public health. J. Hum. Hypertens. 16, 761-770 (2002).
25. Appel, L. J. et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: A call to action from the American Heart Association. Circulation 123, 1138-1143 (2011).
26. Pimenta, E. et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial. Hypertension 54, 475-481 (2009).
27. Sarafidis, P. A. Epidemiology of resistant hypertension. J. Clin. Hypertens. (Greenwich) 13, 523-528 (2011).
28. Gupta, A. K. et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J. Hypertens. 29, 2004-2013 (2011).
29. Yoshita, K. et al. Relationship of alcohol consumption to 7 year blood pressure change in Japanese men. J. Hypertens. 23, 1485-1490 (2005).
30. Li, D., Zhao, H. & Gelernter, J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (.*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum. Genet. 131, 725-737 (2012).
31. Pimenta, E. et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest http://dx.doi.org/10.1378/chest.12-0802.
32. Clark, D., Ahmed, M. I. & Calhoun, D. A. Resistant hypertension and aldosterone: An update. Can. J. Cardiol. 28, 318-325 (2012).
33. Mulatero, P. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. 89, 1045-1050 (2004).
34. Funder, J. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 9, 3266-3281 (2008).
35. Mulatero, P. et al. Drug effects on aldosterone/plasma renin activity in primary aldosteronism. Hypertension 40, 897-902 (2002).
36. Pedrosa, R. P. et al. Obstructive sleep apnea. The most common secondary cause of hypertension associated with resistant hypertension. Hypertension 58, 811-817 (2011).
37. Dudenbostel, T. & Calhoun, D. A. Resistant hypertension, obstructive sleep apnoea and aldosterone. J. Hum. Hypertens. 26, 281-287 (2012).
38. Lozano, L. et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: A randomized, controlled trial. J. Hypertens. 10, 2161-2168 (2010).
39. Kohler, M. & Stradling, J. R. Mechanisms of vascular damage in obstructive sleep apnea. Nat. Rev. Cardiol. 7, 677-685 (2010).
40. Parati, G. & Esler, M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur. Heart J. 33, 1058-1066 (2012).
41. Ruilope, L. M. & Schmieder, R. Current status of renal denervation in resistant hypertension. J. Am. Soc. Hypertens. 6, 414-416 (2012).
42. Persell, S. D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57, 1076-1080 (2011).